{
    "nct_id": "NCT05261399",
    "official_title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",
    "inclusion_criteria": "* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.\n* Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.\n* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.\n* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.\n* Mandatory provision of FFPE tumour tissue.\n* MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.\n* Measurable disease as defined by RECIST 1.1.\n* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.\n* ECOG performance status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Predominant squamous NSCLC, and small cell lung cancer.\n* Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.\n* Prior or current treatment with savolitinib or another MET inhibitors.\n* Spinal cord compression or brain metastases, unless asymptomatic and are stable.\n* History or active leptomeningeal carcinomatosis.\n* Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL.\n* Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.\n* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.\n* Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.\n* Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.\n* Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.\n* Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.",
    "miscellaneous_criteria": ""
}